Literature DB >> 6695945

Clinical importance of "breakthrough" bacteremia.

M P Weinstein, L B Reller.   

Abstract

Fifty-one episodes of bacteremia and a single episode of fungemia occurred during treatment with seemingly adequate doses of appropriate antibiotics. Clinical findings in these "breakthrough" bacteremias and fungemia were compared with those in 448 non-breakthrough episodes. Breakthrough was more likely to be caused by facultative or aerobic gram-negative rods (e.g., Enterobacteriaceae and Pseudomonas species) than by anaerobes. Of the underlying conditions examined, immunosuppressive doses of glucocorticosteroids, diabetes mellitus, and moderate renal failure were significantly more frequent in patients with breakthrough. A significant association was also observed between an intra-abdominal primary focus of infection (abscesses, biliary tract or bowel infections) and the occurrence of breakthrough. Mortality in breakthrough bacteremia was 61 percent compared with 40 percent in non-breakthrough episodes. The phenomenon of breakthrough bacteremia shows the potential limitations of antibiotic therapy alone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6695945     DOI: 10.1016/0002-9343(84)90770-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Nosocomial gram-negative pneumonia in critically ill patients. A 3-year experience with a novel therapeutic regimen.

Authors:  C P Stoutenbeek; H K van Saene; D R Miranda; D F Zandstra; D Langrehr
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

2.  Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.

Authors:  Ji-Yong Lee; Cheol-In Kang; Jae-Hoon Ko; Woo Joo Lee; Hye-Ri Seok; Ga Eun Park; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

3.  Duration of antibiotic therapy for critically ill patients with bloodstream infections: A retrospective cohort study.

Authors:  Thomas C Havey; Robert A Fowler; Ruxandra Pinto; Marion Elligsen; Nick Daneman
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

4.  Anaerobic bacteremia in a cancer center.

Authors:  L M Noriega; P Van der Auwera; M Phan; D Daneau; F Meunier; J Gerain; M Aoun
Journal:  Support Care Cancer       Date:  1993-09       Impact factor: 3.603

5.  Clinical characteristics and prognosis of bacteraemia during postoperative intra-abdominal infections.

Authors:  Adel Alqarni; Elie Kantor; Nathalie Grall; Sebastien Tanaka; Nathalie Zappella; Mathieu Godement; Lara Ribeiro-Parenti; Alexy Tran-Dinh; Philippe Montravers
Journal:  Crit Care       Date:  2018-07-07       Impact factor: 9.097

6.  Timing of follow-up blood cultures for community-onset bacteremia.

Authors:  Ching-Chi Lee; Chao-Yung Yang; Chih-Chia Hsieh; Ming-Yuan Hong; Chung-Hsun Lee; Hung-Jen Tang; Wen-Chien Ko
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

7.  Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study.

Authors:  Julie Oosterbos; Maaike Schalkwijk; Steven Thiessen; Els Oris; Guy Coppens; Katrien Lagrou; Deborah Steensels
Journal:  JAC Antimicrob Resist       Date:  2022-08-23

8.  Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream.

Authors:  A Samet; A Sledzińska; B Krawczyk; A Hellmann; S Nowicki; J Kur; B Nowicki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-07       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.